CAS Number103628-48-4
SynonymsSumatriptan succinate; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide butanedioate (1:1); 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide,butanedioate(1:1); 1-(3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide succinate; 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1); 1-{3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide succinate; 3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl-N-methylmethanesulfonamide Succinate; acide butanedioïque - 1-{3-[2-(diméthylamino)éthyl]-1H-indol-5-yl}-N-méthylméthanesulfonamide (1:1); MFCD00866222; N-[(1-Ethyl-2-pyrrolidinyl)methyl]-2-methoxy-4-sulfamoylbenzamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide butanedioa
Molecular FormulaC18H27N3O6S
Molecular Weight413.49
Purity98.00%
Density1.2±0.1 g/cm3
Boiling Point497.7ºC at 760 mmHg
Melting Point165-166°C
Appearancesolid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 103628-48-4 |
| Catalog No. | 2A-9012545 |
| Chinese Name | 琥珀酸舒马普坦 |
| Synonyms | Sumatriptan succinate; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide butanedioate (1:1); 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide,butanedioate(1:1); 1-(3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide succinate; 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1); 1-{3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide succinate; 3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl-N-methylmethanesulfonamide Succinate; acide butanedioïque - 1-{3-[2-(diméthylamino)éthyl]-1H-indol-5-yl}-N-méthylméthanesulfonamide (1:1); MFCD00866222; N-[(1-Ethyl-2-pyrrolidinyl)methyl]-2-methoxy-4-sulfamoylbenzamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide butanedioa |
| Molecular Formula | C18H27N3O6S |
| Molecular Weight | 413.49 |
| Purity | 98.00 |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 497.7ºC at 760 mmHg |
| Melting Point | 165-166°C |
| Appearance | solid |
| Water Solubility | Water solubility: soluble; water solubility: 170 g |
| Storage Condition | Store at +4°C |
| Application | Sumatriptan succinate (GR 43175) is a 5-HT1 receptor agonist that can treat migraine. |
| HTC | 2935009090 |
| MDL Number | MFCD00902856 |
| SMILES | OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1 |
| InChI | 1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8) |
| InChI Key | PORMUFZNYQJOEI-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/12545_1_103628_48_4.pdf |
| Bioactivity | Sumatriptan succinate (GR 43175) is a serotonin1 (5-HT1) receptor agonist, which is effective in the acute treatment of migraine headache.Target: 5-HT 1d receptor agonistSumatriptan succinate is a serotonin1 (5-HT1) receptor agonist, which is effective in the acute treatment of migraine headache. Its antimigraine activity is believed to derive from selective vasoconstriction of cranial blood vessels which are dilated and distended during migraine headache and/or from inhibition of neurogenically mediated inflammation in the dura mater [1].For sumatriptan succinate 50 mg versus placebo the NNTs were 6.1, 7.5, and 4.0 for pain-free at two hours and headache relief at one and two hours, respectively. NNTs for sustained pain-free and sustained headache relief during the 24 hours postdose were 9.5 and 6.0, respectively [2]. Difference in time-weighted (0-2.5 h) mean arterial pressure MAP (90% confidence interval) was 1.2 mmHg (-0.2, 2.7) between telcagepant and placebo, 4.0 mmHg (2.5, 5.5) between sumatriptan succinate and placebo, and 1.5 mmHg (0.0, 3.0) between telcagepant with sumatriptan succinate vs sumatriptan succinate alone. When coadministered with telcagepant, the AUC0-6h and C(max) of sumatriptan succinate were increased by 23% and 24%, respectively. The small MAP increases observed after coadministration could possibly be associated with the slight elevations in sumatriptan succinate levels [3].Clinical indications: Cluster headache; MigraineToxicity: Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation Related Catalog Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor References [1]. Dechant KL, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. [2]. Derry CJ, et al. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012 Feb 15;2:CD008615. [3]. Depré M, et al. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine. Cephalalgia. 2013 Dec;33(16):1292-301. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 497.7ºC at 760 mmHg Melting Point 165-166°C Molecular Formula C18H27N3O6S Molecular Weight 341.426 Flash Point 254.8ºC Exact Mass 341.140930 PSA 148.18000 LogP 0.34 Vapour Pressure 1.24E-17mmHg at 25°C Index of Refraction 1.552 InChIKey PORMUFZNYQJOEI-UHFFFAOYSA-N SMILES CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O Storage condition Store at +4°C |
| Use of | Properties Articles33 Name sumatriptan succinate Synonym More Synonyms Sumatriptan succinate Biological Activity Related Catalog Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor References [1]. Dechant KL, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. [2]. Derry CJ, et al. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012 Feb 15;2:CD008615. [3]. Depré M, et al. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine. Cephalalgia. 2013 Dec;33(16):1292-301. Chemical & Physical Properties Molecular Formula C18H27N3O6S Exact Mass 341.140930 PSA 148.18000 Index of Refraction 1.552 InChIKey PORMUFZNYQJOEI-UHFFFAOYSA-N |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 35.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Plastic & Specialty Additives | ||
|---|---|---|
| Podophyllotoxin | 518-28-5 | 2A-9012066 |
| Prolyl endopeptidase inhibitor II | 86925-97-5 | 2A-9012144 |
| Rizatriptan | 144034-80-0 | 2A-9012324 |
| Rizatriptan benzoate | 145202-66-0 | 2A-9012325 |
| Sumatriptan | 103628-46-2 | 2A-9012544 |
| Tripamide | 73803-48-2 | 2A-9012854 |
| Triparanol | 78-41-1 | 2A-9012855 |
| Triphosphorustin | 2A-303940 | 2A-9012856 |
| Triptonide | 38647-11-9 | 2A-9012857 |
| Triptophenolide | 74285-86-2 | 2A-9012858 |
| Browse all Plastic & Specialty Additives products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS